Date | Price Target | Rating | Analyst |
---|---|---|---|
4/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
1/3/2024 | $14.00 | Overweight | Barclays |
1/3/2024 | $11.00 | In-line → Outperform | Evercore ISI |
12/13/2023 | $14.00 → $11.00 | Neutral → Overweight | JP Morgan |
11/13/2023 | $12.00 → $11.00 | Neutral → Overweight | Piper Sandler |
8/1/2023 | $16.00 | Overweight | Cantor Fitzgerald |
5/10/2023 | Outperform → Mkt Perform | Raymond James | |
5/10/2023 | Buy → Neutral | Guggenheim |
4 - Health Catalyst, Inc. (0001636422) (Issuer)
4 - Health Catalyst, Inc. (0001636422) (Issuer)
4 - Health Catalyst, Inc. (0001636422) (Issuer)
4 - Health Catalyst, Inc. (0001636422) (Issuer)
SALT LAKE CITY, June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has successfully completed its acquisition of Carevive Systems ("Carevive"), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. Oncology providers and life science researchers use Carevive's flagship platform and/or Carevive data in routine clinical practice for treatment care plan
SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jason Alger, Chief Financial Officer, and Jack Knight, Vice President of Investor Relations, will participate in the following upcoming investor conferences: The Stifel Cross Sector Insight Conference, being held in Boston, including a fireside chat on Tuesday, June 4, 2024, at 9:45am ET.The Goldman Sachs 45th Annual Global Healthcare Conference, being held in Miami, including a presentation on Wednesday, June 12, 2024, at 8:40am ET. About Health Catalyst Heal
SALT LAKE CITY, May 21, 2024 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of Health Catalyst Ignite®, a next-generation healthcare data and analytics ecosystem that combines best-in-class technologies, healthcare-specific data models, self-service tools, and industry expertise in one modern environment. Today's health systems face significant challenges in navigating a path to clinical, operational, and financial success. Rigi
SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2024. "For the first quarter of 2024, I am pleased by our strong financial results, including total revenue of $74.7 million and Adjusted EBITDA of $3.4 million, with these results beating the mid-point of our quarterly guidance on each metric. This financial performance demonstrates our ability to continue to scale our business as we drive toward our long-term profitability goals. We are reiterating our full year 2024 total
8-K - Health Catalyst, Inc. (0001636422) (Filer)
D - Health Catalyst, Inc. (0001636422) (Filer)
8-K - Health Catalyst, Inc. (0001636422) (Filer)
DEFA14A - Health Catalyst, Inc. (0001636422) (Filer)
SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)
SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)
SC 13G - Health Catalyst, Inc. (0001636422) (Subject)
SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)
In the last three months, 4 analysts have published ratings on Health Catalyst (NASDAQ:HCAT), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Health Catalyst, revealing an average target of $11.5, a high estimate of $14.00, and a low estimate of $8.00. A negative shift in sentiment is evident as a
Evercore ISI Group analyst Elizabeth Anderson maintains Health Catalyst (NASDAQ:HCAT) with a Outperform and lowers the price target from $9 to $8.
Throughout the last three months, 4 analysts have evaluated Health Catalyst (NASDAQ:HCAT), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Health Catalyst, presenting an average target of $13.5, a high estimate of $16.00, and a low estimate of $11.00. Marking an increase of 1.28%, the
Piper Sandler analyst Jessica Tassan maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from $15 to $14.
SALT LAKE CITY, June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has successfully completed its acquisition of Carevive Systems ("Carevive"), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. Oncology providers and life science researchers use Carevive's flagship platform and/or Carevive data in routine clinical practice for treatment care plan
Dr. Jennifer Doudna, Dr. Michael Pfeffer, Gregory Robinson & More Join HAS 2024 SALT LAKE CITY, Feb. 2, 2024 /PRNewswire/ -- The Healthcare Analytics Summit (HAS), an annual interactive and educational event for the healthcare industry, today announced its keynote and session speaker lineup for the 2024 event. In its tenth year, HAS 24 is the premier event showcasing data and analytics' critical role in tackling some of healthcare's greatest challenges. HAS 24 convenes national experts whose leadership in data and analytics, machine learning, AI, and healthcare technology have
Carta Healthcare closes series B, triples revenue, and brings in seasoned health tech leader Brent Dover to accelerate growth Health tech company Carta Healthcare®, whose mission is to harness the value of clinical data, is pleased to announce the appointment of Brent Dover as chief executive officer. Dover succeeds former CEO Matt Hollingsworth who co-founded Carta Healthcare in 2017 and who remains a member of the board. In his new role, he will continue to focus on product innovation, business development, and strategic partnerships for Carta Healthcare's market-leading solutions. "I am thrilled to welcome Brent to the Carta Healthcare leadership team. While his expertise in scaling
Announces Appointments of Kevin Freeman as Chief Growth Officer, Tarah Neujahr Bryan as Chief Marketing Officer, and Dave Ross as Chief Technology Officer SALT LAKE CITY, Sept. 7, 2022 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced three new leadership assignments in support of its strategic focus areas moving forward. These strategic focus areas center around strengthening and deepening existing client relationships to enable greater success in realizing massive, measurable, data-informed improvement while continuing to add new client relationships.
4 - Health Catalyst, Inc. (0001636422) (Issuer)
KeyBanc Capital Markets downgraded Health Catalyst from Overweight to Sector Weight
Barclays initiated coverage of Health Catalyst with a rating of Overweight and set a new price target of $14.00
Evercore ISI upgraded Health Catalyst from In-line to Outperform and set a new price target of $11.00
JP Morgan upgraded Health Catalyst from Neutral to Overweight and set a new price target of $11.00 from $14.00 previously
SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2024. "For the first quarter of 2024, I am pleased by our strong financial results, including total revenue of $74.7 million and Adjusted EBITDA of $3.4 million, with these results beating the mid-point of our quarterly guidance on each metric. This financial performance demonstrates our ability to continue to scale our business as we drive toward our long-term profitability goals. We are reiterating our full year 2024 total
USA News Group Commentary VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the largest boost. According to a new research report from analysts at Mordor Intelligence, the market for artificial intelligence in health care is set to explode at a CAGR of 42.20% through 2029. As the tech sector races to provide the market with solutions, several companies are emerging as leaders in aiding the healthcare sector, including Avant Technologies Inc. (OTC:AVAI), Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT), Health Catalyst, Inc. (NASDAQ:HCAT), Ginkgo Bioworks Holdings,
SALT LAKE CITY, April 24, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2024 operating results on Thursday, May 9, 2024, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day. Conference Call Details The conference call can be accessed by dialing 800-267-6316 for U.S. participants, or 203-518-9783 for international participants, and referencing conference ID "HCAT1Q24." A live audio webcast will be available online at https://ir.healthcatalyst.com/. A
SOUTH JORDAN, Utah., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2023. "For the full year 2023, I am pleased to share that we achieved strong performance across our business, including total revenue of $295.9 million, with this result beating the midpoint of our most recent guidance, and Adjusted EBITDA of $11.0 million, with this result in line with the midpoint of our most recent guidance. Additionally, I am pleased by our meaningful 2023 Adjusted EBITDA margin progres